Your Article Summary
See Latest ArticlesShire plc, the global specialty biopharmaceutical company, today announced results from a Phase 3b study that found VYVANSE CII demonstrated significant efficacy at 14 hours after administration during a simulated workplace environment study in adults with Attention Deficit Hyperactivity Disorder. VYVANSE is the first approved stimulant for adults with ADHD to be evaluated in this setting, and these data were presented today at the 49th annual New Clinical Drug Evaluation Unit meeting in Hollywood, FL. VYVANSE is currently approved by the US Food and Drug Administration for the treatment of ADHD in children age 6 to 12 years and in adults with ADHD.
Today in Research & Development...keeping you current
Receive free subspecialty "5-minute updates" via email
Dell Tries to Make an EHR Splash
HealthDataManagement, 11/03/09
Novel agent for treatment of Parkinson's disease - Lu 02-750 - enters Lundbeck's development pipeline
Lundbeck, 11/02/09
Abbott Statement on ARBITER 6 - HALTS Results and Abbotts Niaspan
Abbott, 11/16/09